jcar015
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 21, 2015 (NCT02535364)
Timeline
Indications
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- jcar015
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02973191 | Phase 1/Phase 2 (Phase 2) | Dec 20, 2016 | Celgene, Juno Therapeutics, Inc. |
| NCT02535364 | Phase 2 | Aug 21, 2015 | Juno Therapeutics, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Juno Therapeutics, Inc. | For profit | 2 | 1 | 1 | 2015 |
| Celgene | For profit | 1 | 1 | 1 | 2016 |
2 organizations
Page 1 / 1